Background
: The cytoprotective agent, ecabet sodium, inhibits urease activity and growth of Helicobacter pylori.
Aim
: To evaluate the efficacy and safety of ecabet sodium‐based eradication of H. pylori infection, compared with a lansoprazole‐based regimen, in a randomized multicentre study.
Subjects and methods
: A total of 120 H. pylori‐positive patients were assigned to one of two treatment regimens for 2 weeks: ecabet sodium 1 g b.d., amoxicillin 500 mg t.d.s. and clarithromycin 400 mg b.d. (EAC: 60 patients); or lansoprazole 30 mg (o.m.) with the same antimicrobial agents (LAC: 60 patients). Cure of infection was assessed by a 13C‐urea breath test 1 month after completion of treatment.
Results
: One patient in the EAC group and two in the LAC group did not complete therapy because of an adverse event, and three did not undergo the 13C‐urea breath test. Cure rates for the intention‐to‐treat, all‐patients‐treated and per protocol analysis in the EAC group were 85%, 86% and 88%, respectively, whereas those in the LAC group were 85%, 88% and 91%. There were no significant differences in cure rate or adverse events between the two regimens.
Conclusions
: Ecabet sodium in combination with amoxicillin and clarithromycin is as effective as lansoprazole‐based eradication therapy for H. pylori.
T cell-mediated cytotoxicity via Fas/Fas-L signaling may contribute to the induction of apoptosis in gastric epithelial cells during H. pylori infection.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.